Sugi Predict

Sugi Predict / Compounds / SCHEMBL270386

SCHEMBL270386

SCHEMBL270386

Cc1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1N

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 4/20 0.67
▸ CCND1 P24385 4/20 0.67
▸ BRD4 O60885 10/20 0.60
▸ EGFR P00533 2/20 0.60
▸ CDK2 P24941 2/20 0.59
▸ CCNK O75909 1/20 0.59
▸ CCNA2 P20248 1/20 0.59
▸ CCND3 P30281 1/20 0.59
▸ CDK9 P50750 1/20 0.59
▸ CDK6 Q00534 1/20 0.59
▸ ALK Q9UM73 1/20 0.59
▸ CDK1 P06493 1/20 0.58
▸ FLT3 P36888 2/20 0.57
▸ JAK2 O60674 1/20 0.57
▸ ADRA2A P08913 1/20 0.56
▸ ADRA2C P18825 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30620425 1.00 CDK4 (0.67) CDK4CCND1BRD4EGFRCDK2
SCHEMBL12064950 0.88 CDK4 (0.62) CDK4CCND1BRD4EGFRCDK2
SCHEMBL29777450 0.87 SYK (0.60) CDK4CCND1EGFRCDK2CCNK
SCHEMBL12278146 0.84 BRD4 (0.68) BRD4EGFRCDK2CCNKCCNA2
SCHEMBL2479934 0.83 NPC1 (0.60) CDK4CCND1BRD4EGFRCDK2
SCHEMBL12197982 0.83 CDK4 (0.57) CDK4CCND1BRD4EGFRCDK2
SCHEMBL2951233 0.82 ALK (0.62) CDK4CCND1BRD4EGFRCDK2
SCHEMBL14847406 0.81 EGFR (0.62) CDK4CCND1BRD4EGFRCDK2
SCHEMBL270761 0.81 BRD4 (0.77) BRD4ALKFLT3JAK2
SCHEMBL30306543 0.81 BRD4 (0.77) BRD4ALKFLT3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188041-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA Trustlife Global Inc. 2025-06-12 — — US disclosed
US-10730860-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-08-04 — — US disclosed
US-20190135790-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-05-09 — — US disclosed
US-10150756-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-12-11 — — US disclosed
EP-3099677-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2016-12-07 — — EP disclosed
US-20160332993-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-11-17 — — US disclosed
EP-1951684-B1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN INC (US) 2016-07-13 — — EP disclosed
WO-2015117053-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-08-06 — — WO disclosed
US-8604042-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2013-12-10 — — US disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
WO-2007053452-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332993-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF BRDT, BRD4, BRPF3 CDK4 145/4885CCND1 428/4885BRD4 2/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 CDK4 117/4885CCND1 1012/4885BRD4 142/4885
US-10150756-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof BRDT, BRD4, BRPF3 CDK4 145/4885CCND1 428/4885BRD4 2/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 CDK4 117/4885CCND1 1012/4885BRD4 142/4885
US-20250188041-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA RCC2, GLS, VHL CDK4 287/4885CCND1 780/4885BRD4 2186/4885
US-20190135790-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF BRDT, BRD4, BRPF3 CDK4 145/4885CCND1 428/4885BRD4 2/4885
US-10730860-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof BRDT, BRD4, BRPF3 CDK4 145/4885CCND1 428/4885BRD4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.